Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022

This “Thoracic Aortic Stent Grafts-Pipeline Insight and 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Thoracic Aortic Stent Grafts pipeline landscape. These are essentially used for endovascular repair of abdominal and thoracic aortic aneurysms. Increasing geriatric population, poor dietary habits, and high incidence of Cardiovascular Diseases (CVDs) are some of the factors impelling the demand for novel treatments and devices for thoracic and abdominal aneurysm repair, which, in turn, is expected to drive the market. Smoking, which has become a global concern, is also contributing to the growth of this market. This report provides a detailed study of the emerging Thoracic Aortic Stent Grafts devices along with competitive landscape to help better understand the emerging Thoracic Aortic Stent Grafts devices.

Geography Covered

• Global coverage

Thoracic Aortic Stent Grafts Overview

Thoracic Aortic Stent Grafts: Understanding

The word endovascular refers to the area inside of a blood vessel such as the aorta. Endovascular stent grafting, or endovascular aortic repair (EVAR), is a newer form of treatment for thoracic aortic aneurysms that is less invasive than open surgery. Endovascular stent grafting uses a device called an endovascular stent graft. The endovascular stent graft is a synthetic fabric tube (graft) supported by a metal scaffold (stent).

How does a Thoracic Aortic Stent Grafts work?
During endovascular stent grafting the endovascular stent graft is placed inside thoracic aorta using a long, thin, soft, plastic tube called a delivery catheter. Thoracic aortic aneurysms can weaken the aorta, body's largest blood vessel. This can develop into a potentially serious health problem that can be fatal if the aneurysm bursts, causing massive internal bleeding. The endovascular stent is placed inside of thoracic aorta to help reinforce the blood vessel and prevent the aneurysm from rupturing. The catheter is inserted into an artery in the leg near the groin. Using advanced imaging methods, the surgeon guides the catheter carrying the stent graft to the area of the aneurysm inside the aorta. Once the stent graft is in position, the surgeon deploys it into place and removes the catheter.

Thoracic Aortic Stent Grafts Devices Competitive Assessment

This segment of the Thoracic Aortic Stent Grafts report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.

• Treatment Type

Thoracic Aortic Stent Grafts can be divided based on Treatment Types - Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Abdominal Aortic Aneurysm Repair, Thoracic Aortic Aneurysm Repair & Thoracic Endovascular Aneurysm Repair.

• Major Players in Thoracic Aortic Stent Grafts

There are approx. 20+ key companies which are developing the products for Thoracic Aortic Stent Grafts.

• Nellix System: Endologix

Nellix is being evaluated for its safety and effectiveness. Nellix EndoVascular Sealing System will be implanted into eligible patients. Enrolled patients will undergo a high resolution, contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and aortoiliac vasculature within three months of the scheduled procedure and at specified follow-up intervals post-implantation. The Primary study completion date is March 2025.

• NEXUS: Endospan Ltd.

NEXUS is being developed by Endospan Ltd. The purpose of the study is to evaluate the safety and performance of the Nexus Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic pathologies requiring landing in the Aortic Arch. The Nexus Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic pathologies involving the aortic arch (such as aneurisms and dissections). The device is intended to exclude the lesion from the blood circulation in patients diagnosed with thoracic aortic pathology and who have appropriate anatomy to accommodate the Nexus system in an endovascular procedure. The primary objectives of the study are to evaluate the safety and performance of the Nexus Aortic Arch Aneurysm Stent Graft System. The device is currently available for sale in Europe and is intended for investigational use only in the U.S. The primary study completion date is expected to be October 2023.

Further product details are provided in the report……..

Thoracic Aortic Stent Grafts Competitive Benchmarking
This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

• Brand Positioning of Leading companies
• Application
• Industry Collaborations

Thoracic Aortic Stent Grafts: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of THORACIC AORTIC STENT GRAFTS devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In October 2020 Cook Medical announced that the Zilver Vena received FDA premarket approval (PMA) in the United States. The product is expected to be commercially available to physicians in the U.S. in Q4 2020. Zilver Vena is a self-expanding stent approved to treat patients suffering from iliofemoral venous disease. Venous disease is a condition where the body cannot properly pump blood through veins back to the heart.
• In July 2020, Medtronic plc, the global leader in medical technology, announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissection. The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York, New York by Derek Brinster, M.D., director of Aortic Surgery.

Further commercial activities are provided in the report……..

Thoracic Aortic Stent Grafts: Reimbursement

• US

Medicare sometimes issues coverage policies indicating under what circumstances they will/will not cover a particular medical service or procedure. On occasion, these policies are issued as national coverage policies affecting all Medicare patients. Other times they are issued by local Medicare contractors as local coverage decisions (LCDs) affecting only those Medicare beneficiaries in a given contractor's jurisdiction. At this point in time, Medicare has not issued a national coverage decision about endovascular treatment of thoracic aortic aneurysms.

Further information is provided in the report……..

Report Highlights

• Extensive coverage of the Thoracic Aortic Stent Grafts under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Thoracic Aortic Stent Grafts and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry
• The report consists of in depth analysis of pipeline products based on various parameters

Thoracic Aortic Stent Grafts Report Insights

• Thoracic Aortic Stent Grafts - Pipeline Analysis
• Thoracic Aortic Stent Grafts - Unmet Need
• Thoracic Aortic Stent Grafts - Market Dynamics
• Thoracic Aortic Stent Grafts - Future Perspectives and Conclusion
• Thoracic Aortic Stent Grafts - Analyst Views

Key Questions

• What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?
• How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?
• What are important and diverse types of Thoracic Aortic Stent Grafts under development?
• What are market-entry and market expansion strategies in Thoracic Aortic Stent Grafts?
• What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?
• What is in-depth analysis of the product's current stage of development, territory and estimated launch date?

Key Players

• Cook Medical, Inc
• W.L. Gore & Associates
• Medtronic Plc
• Lombard Medical, Inc
• Endologix, INC
• Terumo Corporation Inc.
• Cardinal Health Inc
• Becton
• Dickinson and Company
• Cryolife Inc.
• MicroPort Scientific Corporation
• Evasc Medical Systems Corp.
• St. Jude Medical, Inc.
• TriVascular and Inc.

This product will be delivered within 3-5 business days.